Basilea Pharmaceutica
Basilea Pharmaceutica AG, commonly referred to as Basilea, is a Swiss biopharmaceutical company headquartered in Basel, Switzerland. Founded in 2000, Basilea focuses on the development and commercialisation of innovative therapies for oncology and infectious diseases. The company has made significant strides in the pharmaceutical industry, particularly with its core products, which include advanced treatments for resistant infections and cancer. Basilea's unique approach combines cutting-edge research with a commitment to addressing unmet medical needs, positioning it as a key player in the global biopharmaceutical landscape. With a strong presence in Europe and North America, Basilea has achieved notable milestones, including successful product launches and strategic partnerships that enhance its market position. The company's dedication to innovation and patient care continues to drive its growth and reputation in the industry.
DitchCarbon Score
How does Basilea Pharmaceutica's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Basilea Pharmaceutica's score of 23 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Basilea Pharmaceutica's reported carbon emissions
Basilea Pharmaceutica, headquartered in Switzerland (CH), currently does not have available carbon emissions data for recent years, as no specific emissions figures have been provided. Consequently, there are no reported Scope 1, 2, or 3 emissions figures to analyse. In the absence of specific emissions data, it is important to note that Basilea Pharmaceutica has not outlined any formal reduction targets or climate commitments. This lack of publicly available information suggests that the company may still be in the early stages of developing a comprehensive climate strategy or reporting framework. As the pharmaceutical industry increasingly prioritises sustainability and climate action, Basilea Pharmaceutica's future commitments and initiatives will be crucial in aligning with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Basilea Pharmaceutica is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
